# Detergents without a drain: the evolutionary logic (and liability) of sphingolipids

## TL;DR

Sphingolipids evolved to manage fatty acid toxicity but become harmful in modern conditions of excess lipids, contributing to chronic diseases like diabetes and heart failure.

## Contribution

The paper proposes that sphingolipids evolved as a biochemical solution to fatty acid detergent stress and become pathological under chronic lipid surplus.

## Key findings

- Sphingolipid metabolism stabilizes membranes and enables ceramide-dependent signaling to manage lipid overload.
- Excessive sphingolipid accumulation in tissues like liver and adipose contributes to metabolic inflexibility and chronic diseases.
- Circulating ceramides are linked to cardiometabolic risk and play causal roles in disease progression in rodent models.

## Abstract

Sphingolipids are evolutionarily conserved lipids that, I contend, emerged as a solution to a fundamental biochemical problem: cells require fatty acids, yet these molecules are potent detergents. In higher metazoans, a metabolic asymmetry amplifies this physical threat: unlike most macronutrients, fatty acids cannot be readily converted into nonlipid forms of biomass. Thus, when their supply exceeds energetic demand, they remain chemically committed lipids with the capacity to destabilize membranes and disrupt cellular organization. The emergence of sphingolipid metabolism offered an elegant solution to this challenge. By incorporating fatty acids into sphingolipids, cells both stabilize membranes to combat detergent stress and generate ceramide-dependent signaling programs that coordinate metabolic adaptation, remodeling, and, when necessary, cell elimination in response to lipid overload. In modern settings of chronic lipid surplus, most prominently obesity, this otherwise adaptive system becomes pathological. Across liver, adipose tissue, skeletal muscle, heart, pancreas, and kidney, excessive sphingolipid accumulation enforces metabolic inflexibility, impairs mitochondrial efficiency, and promotes cell dysfunction or loss, contributing to diabetes, steatohepatitis, heart failure, and kidney disease. Human studies consistently associate circulating ceramide species with cardiometabolic risk, while interventional studies in rodents demonstrate their causal roles in disease progression. Together, these findings position sphingolipids—much like cholesterol—as both early biomarkers and modifiable drivers of chronic disease, highlighting how an evolutionary solution becomes pathogenic in the setting of prolonged nutrient excess.